Source file signed link, expires in 15 minutes
Extracted text 8
Page 1
March 30th, 2026
PUBLIC EXPOSE 2026
PT DIASTIKA BIOTEKINDO TBK (CHEK)
A. COMPANY OVERVIEW
Special points of Diastika Biotekindo is a high growth diagnostics and life
interest:
science distributor company, which focusing on genomic and
COMPANY blood bank in the past few years that positioned at the center
HIGHLIGHT of Indonesia healthcare transformation.
BUSINESS
MODEL Provide critical laboratory technologies, molecular
diagnostics systems, and genomics solutions to hospitals,
C. SALES
STRATEGY labs, research institutions, F&B Industries and government
programs. With a rapidly expanding installation base and
D. PRODUCT
PORTOFOLIO embedded reagent demand, CHEK offers resilient healthcare
exposure with scalable earnings growth.
Positioned to benefit from structural expansion in healthcare
spending, molecular testing adoption, and national genomic
initiatives. Consistent revenue expansion, CHEK continues to
demonstrate structurally consistent performance supported
by growth in diagnostic and life science solutions.
Inside this issue: B. BUSINESS MODEL D. PRODUCT PORTOFOLIO
Two Core Segments: 1. General Lab
INDUSTRY 2
POSITIONING 1. Clinical Diagnostics 2. Life Science
EQUITY 3 3. Blood Bank
STORY AT
2. Life Science
GLANCE 4. Chemistry
Revenue Streams:
SALES 4
1. Instruments (one off/project based) 5. Hematology
HIGHLIGHT
CUSTOMER 6 2. Consumables & reagent (contracted) 6. Immunology
OVERVIEW
3. Maintanance & Service 7. Genomic Sequencing
FINANCIAL 7
HIGHLIGHT 8. Cold Chain
BUSINESS 8 9. CLIA
EXPANSION
HIGHLIGHT 10. Molecular
C. SALES STRATEGY
1. Direct sales - hospitals, labs, research institutions, F&B Industries and Blood
Bank (UTDRS, PMI)
2. Operational partnerships - long term contracts
3. Tender/procurement large scale projects
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220-I
Email: Corpsec@diastika.co.id
Page 2
Page 2
PUBLIC EXPOSE 2026
CHEK INDUSTRY POSITIONING
In terms of competitive positioning, CHEK is a strategic player within Indonesia
diagnostic and life science market, competing with both multinational distributor
and local peers. CHEK strengths lie in integrated product offering, and strong
distribution capabilities, which collectively support consistent business growth
and customer retention. To further enhance its market position, CHEK focuses on
expanding its product portfolio, strengthening partnerships with global principals,
and capturing opportunities across both government and private sector demand.
qTOWER Iris Series Real Time
Thermal Cycler (qPCR) This strategy underscores its commitment to achieving scalable and sustainable
long-term growth.
Indonesia’s medical device industry
1. Market size USD 2.3–2.6 billion in 2025
2. CAGR estimated at 8%–12%
3. High dependency on imports (>70%)
4. Opportunities in diagnostics & lab segments
DNBSEQ-G99—Unleash Your
Ultimate Sequencing Speed
5. Strong need for integrated solutions
Diagnostic Laboratory Market
1. Market-size for diagnostic laboratory estimated around USD 1.4–1.5 billion
in 2025.
2. CAGR estimated 8–8.1% 2025–2032.
3. Projection for lab diagnostic and related services ASEAN and Indonesia
estimated 7–7.8% CAGR
4. Lab expansion nationwide
Sorvall WX100+ Ultra speed
Centrifuge
Variant II Hemoglobin Testing
System
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 3
Page 3
PUBLIC EXPOSE 2026
EQUITY STORY AT A GLANCE
1. Market Leadership & Sustainable Competitive Advantage —As the established market leader in
diabetes testing and a premier provider of third party Quality Control (QC) solutions, CHEK holds a
dominant position in chronic disease management with clients spanning from renowned hospital
group, lab chain, government institution. This high-barrier entry ensures a defensive asset position
in the healthcare sector.
2. Stable Revenue Stream—Revenue model is anchored by a strong margin "razor and blade" model
where installed instruments drive stable demand for reagents and consumables. This structure
ensures sustainable revenue and long term cash flow visibility.
3. Broad Institutional Adoption—CHEK is driving growth in clinical testing, molecular diagnostics, and
genomics across hospitals, laboratories, and research institutions. This modernization ensures
diversified revenue streams across both private and public sectors.
4. Strategic Positioning in Indonesian Healthcare—CHEK is the leading diagnostics and life science
solutions provider in Indonesia. strategically positioned within the national healthcare ecosystem
and serving as a key gateway to the country largest healthcare market. Our product are present
nationwide across healthcare ecosystem from blood bank, labs clinic and hospitals.
5. Genomics infrastructure platform the making—By building the nations premier genomics
infrastructure platform, CHEK has secured an early mover advantage. This establishes an
indispensable foundation for the future personalized medicine and genetic research in Indonesia.
Revenue by Customer Segment Revenue by Service Line
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 4
Page 4
PUBLIC EXPOSE 2026
SALES HIGHLIGHT
Our Diagnostic division continues to
show healthy, consistent growth with
a 21.26% increase, This represents
our stable, high-trust revenue base.
The High-Growth Rocket The most
thrilling story is in Life Science, which
has experienced a phenomenal
57.24% year-over-year explosion.
Revenue is dominated by the
Consumables category, which
shows significant growth from IDR
118 billion in 2024 to IDR 168 billion
in 2025. This category reflecting
strong and sustained demand for
consumable products that support
genomic and diagnostic services.
Our primary driven, Consumables,
has seen a massive 28.17%
year-over-year surge, jumping from
157,545 to 201,931 units/pcs.
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 5
Page 5
PUBLIC EXPOSE 2026
1. Strong YoY Growth: Revenue increased significantly across all quarters in 2025 compared to
2024.
2. Consistent Momentum: Steady growth from Q1 to Q4 reflects healthy demand and solid
execution.
3. Q4 Breakout: A sharp surge in Q4 (72.47% YoY) became the key driver of annual growth, indicat-
ing strong acceleration and potential seasonality heightened activity from regional government
projects and ministry of health. A Sales spike Q4 2025 sustain partly by genomic projects from
research and educational institutions (including GeneBank)
4. Positive Outlook: The trend highlights a scalable business model with clear runway for further
expansion.
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 6
Page 6
PUBLIC EXPOSE 2026
CUSTOMER OVERVIEW
• Strong Inherent Revenue: 60% of
revenue is driven by existing
business, indicating high customer
retention and sustainable income.
• Expansion Within Base: 28%
contribution from new business
reflects successful upselling and
cross selling strategies.
• New Customer Pipeline: 12% from
new customers demonstrates
ongoing market expansion and
client acquisition efforts.
• Broad-Based Growth: All segments recorded strong YoY growth in 2025, demonstrating diversified
revenue expansion.
• Key Growth Drivers: Government lab, private hospitals, and government hospitals, the increase,
indicating strong institutional demand.
• Core Segment Stability: Private laboratories remain the largest contributor with steady growth,
reinforcing a solid revenue base.
• Emerging Upside: Smaller segments (food & beverage, research, blood banks) showed consistent
gains, highlighting additional growth levers.
• Positive Mix Evolution: Balanced contribution across public and private sectors supports resilience
and long-term scalability.
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 7
PUBLIC EXPOSE 2026
Page 7
FINANCIAL HIGHLIGHT
31 December 2025 31 December 2024 31 December 2023
ITEM
Net Revenue IDR 201.306.181.384 IDR 129.097.723.199
IDR 154.791.849.692
Operating Profit IDR 23.153.085.596 IDR 15.276.096.516
IDR 21.494.529.007
Cost of Goods Sold
IDR 124.166.227.855 IDR 94.072.770.495 IDR 79.508.532.611
Profit & Loss
Gross Profit IDR 77.139.953.529 IDR 60.719.079.197
IDR 49.589.190.588
Operating Ex-
penses IDR 53.986.867.933 IDR 39.224.550.190 IDR 34.313.094.072
Net Profit
IDR 14.023.055.375 IDR 15.174.534.611 IDR 13.590.738.807
ITEM 31 December 2025 31 December 2024 31 December 2023
Total Asset IDR 259.530.017.664 IDR118.809.484.550 IDR 97.494.535.464
Total Liabilitas IDR 48.448.437.530 IDR 25.566.981.540 IDR 19.236.805.126
Balance Sheet Total Equity IDR 211.081.580.134 IDR 93.242.503.010 IDR 78.257.730.338
Total Liabilitas and
IDR 259.530.017.664 IDR 118.809.484.550 IDR 97.494.535.464
Equity
1. Strong Revenue Growth: Net revenue reached IDR 201B (+30% YoY), reflecting solid top-line
expansion.
2. Consistent Profitability: Gross profit increased 27.04% to IDR 77.1B, while operating expenses
remained controlled, supporting operational efficiency.
3. Asset Expansion: Total assets more than doubled (+118% YoY) to IDR 259B, signaling aggressive
growth and capacity build-up.
4. Leverage Increase: Liabilities surged significantly, suggesting increased funding to support
expansion initiatives.
5. Stronger Equity Base: Equity grew 126% YoY, reinforcing balance sheet strength post-IPO
6. Overall Positioning: CHEK is in a high growth phase scaling rapidly with strong revenue
momentum, while navigating short term profitability trade offs.
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building 3rd
Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI Jakarta, 13220
Email: Corpsec@diastika.co.id
Page 8
PUBLIC EXPOSE 2026
Page 8
BUSINESS EXPANSION HIGHLIGHT
1. Expanding Installed Base Across Hospitals and Laboratories - The Company continued deployment
of diagnostic and laboratory equipment across hospitals, clinical labs, and research institutions is
strengthening the Company core revenue base through higher reagent and consumables usage.
2. Scaling Presence in Molecular Diagnostics and Genomics - The Company is increasing its footprint
in molecular testing and genomics solutions, positioning itself to capture rising demand for precision
diagnostics and advanced laboratory capabilities in Indonesia. This further supported by its strong
diagnostic portfolio, including gold-standard HPLC based diabetes testing, QC third-party services,
and rapidly growing genomic sequencing offerings, which recorded up to 136% YoY growth
3. Deepening Partnerships with Global Principals - Strategic collaboration with leading international
manufacturers enables access to advanced technologies, supports product portfolio expansion, and
reinforces the Company competitive positioning in high growth diagnostic and research segments.
4. New Entry to Radiology Business - The Company is set to launch its own brand of Mobile X-Ray units
as a strategic cornerstone for product diversification. This initiative is designed to capture higher profit
margins through vertical integration and domestic production autonomy, while significantly expanding
the company medical hardware portfolio. By offering proprietary portable imaging solutions. The
Company is uniquely positioned to serve the growing demand for decentralized healthcare and remote
diagnostic services across Indonesia.
5. Empowering National Blood Banks - New regulations (Government Regulation PP 28/2024 and
BPOM Regulation No. 17 of 2024 & No. 11 of 2025 Standards, Minister of Health Decree (KMK) No. 504
of 2024, Mandatory UTD Accreditation Kepdirjen No. HK.02.02/D/15603/2023) create a significant
'barrier to entry' that favors sophisticated, compliant healthcare providers. For an integrated hospital,
having a self-managed UTDRS is now a critical competitive advantage, ensuring supply chain security,
pharmaceutical-grade quality control, as more hospitals building their own blood bank CHEK will be
perfectly positioned to be the key supporting partners. The inclusion of the blood bank segment further
expands the addressable market, the healthcare service ecosystem, particularly in the areas of blood
testing and processing, and the screening of specific infectious diseases, which is rapidly growing in
Indonesia.
6. Lowering Dependency to Imports - 2026 expansion strategy focuses on strengthening TKDN
compliant products, enabling broader penetration into key institutional segments including
government laboratories, hospitals, health offices. This TKDN driven expansion positions the
Company to capture growing demand from public sector procurement while supporting Indonesia
national agenda to increase the use of domestically produced medical and laboratory technologies.
Head Office: Jakarta Industrial Estate Pulogadung. Rawa Gelam V Blok L, Kav. 11-13, Etana Building
3rd Floor, Jatinegara, Cakung, East Jakarta, DKI Jakarta 13930 – Indonesia.
Warehouse: Pemuda No.61 KAV.30- 31, RT 009 RW 003, Rawamangun, Pulogadung, East Jakarta, DKI
Jakarta, 13220-Indonesia.
Email: Corpsec@diastika.co.id
Names mentioned 3 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Bank STORY AT
p.1
unresolved
org
Minister of Health Decree
p.8
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.